ANI Pharmaceuticals (ANIP) FY2020 results: revenue $208 million, up 0.9% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $208 million for fiscal 2020, the year ended 31 December 2020, up 0.9% on the year before. Net income was -$23 million, and diluted earnings per share $-1.88. The figures are the company's own, from the 10-K it filed with the SEC on 11 March 2021.
Revenue
$208 million
+0.9% on the year
FY2013FY2020
Operating margin
-7.7%
7.9% a year earlier
FY2013FY2020
Net income
-$23 million
FY2013FY2020
Diluted EPS
-$1.88
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
208
207
202
+0.9%
Cost of revenue
87.2
63.2
73.0
+38.0%
Gross profit
121
143
129
-15.4%
Gross margin
58.2%
69.4%
63.8%
Research and development
16.0
19.8
15.4
-19.2%
Selling, general and administrative
65.0
55.8
44.1
+16.4%
Operating income
-16.0
16.4
35.4
Operating margin
-7.7%
7.9%
17.5%
Interest expense
9.5
13.5
14.9
-29.6%
Pre-tax income
-26.0
3.2
20.1
Income tax
-3.4
-2.9
4.6
Effective tax rate
n/a
-93.0%
22.7%
Net income
-22.5
6.1
15.5
Net margin
-10.8%
3.0%
7.7%
Diluted EPS
-$1.88
$0.50
$1.30
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
15.3
45.6
67.1
-66.5%
Capital expenditure
6.1
6.6
5.7
-7.5%
Free cash flow
9.1
39.0
61.3
-76.6%
Free cash flow margin
4.4%
18.9%
30.4%
Cash from investing
-68.3
-27.5
-27.4
Cash from financing
-1.4
1.2
-27.8
Depreciation and amortisation
44.6
44.6
33.7
+0.1%
Share-based compensation
12.9
9.2
6.8
+40.3%
Buybacks
1.5
1.0
0.0
+47.7%
Dividends paid
0.0
0.0
n/a
Diluted shares, weighted
12m
12m
12m
-0.6%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
196
213
197
-8.0%
Redeemable equity
0.0
n/a
n/a
Debt
186
186
183
-0.0%
Operating lease liabilities
0.2
0.3
n/a
-41.1%
Other liabilities
79.6
58.0
50.3
+37.4%
Total liabilities and equity
461
457
431
+1.0%
Fixed assets
41.3
40.6
38.1
+1.8%
Goodwill
3.6
3.6
3.6
0.0%
Intangible assets
189
180
202
+4.5%
Cash and equivalents
7.9
62.3
43.0
-87.4%
Receivables
95.8
72.1
64.8
+32.8%
Inventory
60.8
48.2
40.5
+26.2%
Other assets
63.4
49.6
39.0
+27.6%
Total assets
461
457
431
+1.0%
10-K for the year ended 31 December 2020, filed 11 March 2021: the filing.